Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

Published Date: 10 Apr 2024

Patients with surgically removed HPV-negative head and neck squamous cell cancer (HNSCC) experienced low rates of disease relapse after receiving the personalized neoantigen vaccine TG4050, which stimulated tumor-specific immune responses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More pain, more gain? New biopsy technique found to improve prostate cancer detection

2.

AI-based liquid biopsy shows promise for detecting brain cancer

3.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

4.

When Should Immunocompromised Individuals Receive a COVID Booster?

5.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot